TP53 and neoplasm: SIM0501 (USP1 inhibitor) disrupted DDR-associated ubiquitination to suppress tumor proliferation [24]; GH2616 inhibited KIF18A, impairing spindle-centromere attachment [25]; AZD3470, a second-generation PRMT5 inhibitor, selectively targeted MTA-deficient tumors with reduced toxicity [26]; and HRO761 promoted WRN degradation, activating p53-mediated apoptosis in microsatellite instability tumors [27].